NAMS (NewAmsterdam Pharma Co NV) YoY EBITDA Growth: -255.48% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NAMS NewAmsterdam Pharma Co NV NAMS
50 GF Score
Price $21.16
GF Value $14.98
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is NewAmsterdam Pharma Co NV YoY EBITDA Growth?

NewAmsterdam Pharma Co NV NAMS -5.37% 50 YoY EBITDA Growth is -255.48% as of Jun. 2026. GuruFocus rates NAMS with a GF Score™ of 50/100 and a GF Value™ of $14.98 (Significantly Overvalued). The stock has 3 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. NewAmsterdam Pharma Co NV's YoY EBITDA Growth for the quarter that ended in Jun. 2026 was -255.48%.

NewAmsterdam Pharma Co NV's EBITDA per Share for the three months ended in Jun. 2026 was $-0.52.

NewAmsterdam Pharma Co NV YoY EBITDA Growth Related Terms

NewAmsterdam Pharma Co NV YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for NewAmsterdam Pharma Co NV's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NewAmsterdam Pharma Co NV YoY EBITDA Growth Chart

NewAmsterdam Pharma Co NV Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EBITDA Growth
Get a 7-Day Free Trial 11,650.00 -601.28 -82.77 -18.86 32.83

NewAmsterdam Pharma Co NV Quarterly Data
Dec20 Dec21 Jun22 Jun23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 64.56 -245.71 31.09 -16.77 -255.48
NAMS
50GF Score
NewAmsterdam Pharma Co NV NAMS
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NewAmsterdam Pharma Co NV YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

NewAmsterdam Pharma Co NV's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(-1.719--2.559)/ | -2.559 |
=32.83 %

NewAmsterdam Pharma Co NV's YoY EBITDA Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EBITDA Growth (Q: Jun. 2026 )
=(EBITDA per Share (Q: Jun. 2026 )-EBITDA per Share (Q: Jun. 2025 )) / | EBITDA per Share (Q: Jun. 2025 )) |
=(-0.519--0.146)/ | -0.146 |
=-255.48 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of -255.48% mean?
NewAmsterdam Pharma Co NV (NAMS) has a YoY EBITDA Growth of -255.48% as of Jun. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for NewAmsterdam Pharma Co NV and its competitors.
Is NewAmsterdam Pharma Co NV's YoY EBITDA Growth too high?
NewAmsterdam Pharma Co NV's current YoY EBITDA Growth is -255.48%. Overall, NewAmsterdam Pharma Co NV has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NewAmsterdam Pharma Co NV's YoY EBITDA Growth compare to IRON and CLDX?
NewAmsterdam Pharma Co NV's YoY EBITDA Growth of -255.48% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Biotechnology company?
A good YoY EBITDA Growth depends on the Biotechnology industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for NewAmsterdam Pharma Co NV and its competitors. NewAmsterdam Pharma Co NV's current YoY EBITDA Growth is -255.48%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NewAmsterdam Pharma Co NV stock overvalued right now?
Based on GuruFocus' analysis, NewAmsterdam Pharma Co NV (NAMS) is currently considered Significantly Overvalued. The stock's GF Value™ is $14.98, compared to a current price of $21.16 — trading 41.3% above its estimated fair value. The current YoY EBITDA Growth is -255.48%. NewAmsterdam Pharma Co NV's overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For NewAmsterdam Pharma Co NV (NAMS), the current YoY EBITDA Growth is -255.48% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NewAmsterdam Pharma Co NV (NAMS) Overvalued in 2026?

Based on GuruFocus' analysis, NewAmsterdam Pharma Co NV stock appears to be overvalued. The current stock price of $21.16 is trading 41.3% above its estimated GF Value™ of $14.98. GuruFocus considers NewAmsterdam Pharma Co NV to be Significantly Overvalued.

Key valuation signals for NAMS:

  • YoY EBITDA Growth: -255.48%
  • GF Value™: $14.98 vs. price of $21.16 (41.3% above fair value)
  • GF Score™: 50/100 with 3 warning signs

No single metric tells the full story. See the NAMS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

NewAmsterdam Pharma Co NV Business Description

Other Exchanges KH6:Germany
Address Gooimeer 2-35, Naarden, NH, NLD, 1411 DC
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
50GF Score

Get the complete analysis for NAMS

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$21.16
Price
$14.98
GF Value